Image Source: TREATMERIGHTMS
Saturday, June 25
High cumulative JC virus seroconversion rate during long-term use of Tysabri (natalizumab): STUDY
Image Source: IMAGEARCADE
Wednesday, April 27
Tysabri (Natalizumab) Targets Molecule Crucial for Type of B-Cell to Accumulate in the Brain
Mice with experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS), were found to have milder symptoms if the target of natalizumab (Tysabri) — VLA4 — was absent on B-cells, preventing regulatory cells that might control immune processes from entering the brain.
Disrupted balance of T cells under Tysabri (natalizumab) treatment in MS: STUDY
Image Source: THINKINGMACHINEBLOG
MS drug influences John Cunningham virus antibody levels
Image Source: UNI-MUENSTER
The multiple sclerosis treatment Tysabri (natalizumab) may be associated with increased levels of John Cunningham virus antibodies, indicating increased risk for fatal brain disease caused by the infection, according to recent data.
Disease-modifying treatments for MS – a review of approved medications: STUDY
Image Source: THEBRINLEYFAMILY
Wednesday, April 20
Monitoring the John Cunningham virus throughout Tysabri (natalizumab) treatment in MS patients: STUDY
HISTOLOGY: NERVOUS: BRAIN: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY, PML; MULTINUCLEATED ASTROCYTE
Image Source: PEIRDIGITALLIBRARY
Thursday, April 7
Biogen to Highlight Broad Research Commitment to MS Care at ECTRIMS Congress, Including New TECFIDERA® Data Demonstrating Importance of Early Treatment
Biogen (BIIB) will present new clinical data for its multiple sclerosis (MS) portfolio of therapies, including the most-prescribed oral treatment, TECFIDERA® (dimethyl fumarate), at the 31st meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain, 7-10 October 2015.1 TECFIDERA data will demonstrate its strong and sustained efficacy in relapsing-remitting multiple sclerosis (RRMS) among patients who were early in the course of their disease or newly diagnosed.
Switching from Tysabri to Tecfidera: VIDEO
Dr. Daniel Kantor talks about switching from Tysabri to Tecfidera and the outcomes.
Click here to see more
Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy (PML): Risks and Detection: VIDEO
Fred Lublin, MD, explains that prior to the use of Tysabri (natalizumab), progressive multifocal leukoencephalopathy (PML) had never been observed in patients with multiple sclerosis (MS). Providing accurate figures about the risk of PML to patients who may be or are being treated with natalizumab iscritically important in makingthe best treatment choices. PML is not as severe and lethal in the setting of MS as in other diseases, such as HIV. Still, he adds,PML often leaves individuals left with some kind of disability, and the mortality rate in MS is about 20%.
Saturday, July 25
NHS Wales Approves Biogen’s Plegridy for Relapsing Remitting MS
Relapsing remitting multiple sclerosis (RRMS) treatment Plegridy (peg interferon beta-1a) by Biogen Idec, has just received Welsh NHS approval, which should make it available to patients by late October 2015. The decision follows NHS Scotland’s approval earlier this year, however, the biweekly interferon beta shot has yet to be made available in England’s NICE healthcare system. Plegridy was approved across several countries in the European Union in July of 2014.
New MS Study Shows TYSABRI Improves Cognitive Impairment
Thursday, July 2
Researchers Suggest Short Transition Period Between Tysabri (Natalizumab) and Gilenya (Fingolimod) Therapies to Control RRMS Disease Activity
An international team led by researchers at the University Hospital Basel in Switzerland revealed that a short period of 8 to 12 weeks is the optimal timing to be considered when patients with relapsing-remitting multiple sclerosis (RRMS) are switched from natalizumab to fingolimod therapy. The study was recently published in the journal Neurology and is entitled “Switching from natalizumab to fingolimod, A randomized, placebo-controlled study in RRMS.”
Study tests safety & efficacy of new treatment intervals for MS therapy Tysabri (Natalizumab)
A new study presented last week during the American Academy of Neurology’s 67th Annual Meeting in Washington, DC provides new treatment strategies for multiple sclerosis (MS) using a monoclonal antibody already used in some MS patients.
Sunday, May 3
Thursday, April 16
Is $13,000 a dose too much for a medicine: VIDEO
One hundred thousand dollars a year. That’s how much a specialty drug can cost. They’re newer medicines for diseases like multiple sclerosis, hepatitis C and cancer. Many insurers and others say the costs are bankrupting our health care system.
Wednesday, April 8
FREE MS RESEARCH UPDATE: a comprehensive overview of research findings on all of the FDA-approved disease-modifying therapies, as well as many experimental treatments
This year's expanded MS Research Update incorporates new information about the approved disease-modifying therapies (DMTs), as well as numerous experimental drugs currently under investigation for the long-term treatment of multiple sclerosis (MS). Highlights and recent research results are provided for each drug. Please note that symptom-management drugs are not included in this report.
DOWNLOAD YOUR FREE PDF OR ORDER A FREE COPY
Sunday, March 29
Sunday, March 15
Saturday, February 7
Saturday, January 10
Immunological biomarkers identifying Tysabri (natalizumab)-treated multiple sclerosis patients at risk of progressive multifocal leukoencephalopathy
Progressive Multifocal leukoencephalopathy (PML)
Tecfidera-Related Progressive Multifocal Leukoencephalopathy (PML) Reported
Los Angeles, CA: The first known incidence of PML, or progressive multifocal leukoencephalopathy, in a patient taking Tecfidera, has been confirmed by Biogen Idec, the maker of the new treatment for multiple sclerosis (MS).
Neurology Times Provides Special Coverage of Multiple Sclerosis
UBM Medica US reported at that Neurology Times, an online community and information resource for neurologists and other healthcare providers features special coverage on multiple sclerosis, devoted to fostering better treatment of patients who have the disorder.
Findings on Monoclonal Antibodies Detailed by Investigators at University Hospital - Tysabri (Natalizumab) treatment alters the expression of T-cell trafficking...
According to news reporting originating from Lausanne, Switzerland, by NewsRx correspondents, research stated, "To determine the long-term effect of natalizunnab (NTZ) treatment on the expression of integrins and chenmokine receptors involved in the migration of T cells towards the central nervous system (CNS). We drew the blood of 23 patients just before starting NTZ therapy and every 12 months thereafter, for up to 48 months of treatment."
My only hope is stem cell op - MS mum
Celine Walsh is in the second stage of Multiple Sclerosis and doctors have told the mother they can do nothing more for her condition.
BREAKING NEWS: TYSABRI HELPS INCREASE WALKING SPEED
NEW STUDY IS OUR FEATURE STORY IN TOMORROW'S NEWS
Will the anti-B-cell therapies (Rituximab) supplant Campath (alemtuzumab) and Tysabri (natalizumab) in MS?
"Rituximab is a B cell depleting agent that works in MS. The phase 2 results were spectacular and shifted the paradigm in MS. The anecdotal experience from the off-label use of rituximab in MS has confirmed this; I have personally used rituximab in a handful of cases and have been very impressed with its ability to switch-off disease activity."
"Due to complex, scientific and business, reasons Genentech-Roche decided against taking rituximab forward in MS. Instead they decided to develop the follow-on compound ocrelizumab. This latter decision will delay the access of an anti-CD20 therapy for MSers by about 4 years.
Friday, May 16
S*** NHS England green-lights switch from Tysabri to Gilenya in MSers at high-risk of PML
NHS England green-lights switch from natalizumab to fingolimod in MSers at high-risk of PML#MSBlog #MSResearch #ClinicSpeak
Interferon-beta, GA or steroids not good enough to prevent rebound activity #MSBlog #MSResearch #ClinicSpeak
"The
study below confirms what we already know; stopping natalizumab leads
to rebound in MS disease activity. Switching to a DMT on a lower-tier of
efficacy, i.e. interferon-beta or glatiramer acetate, or taking
steroids does not prevent this rebound. In comparison, a higher-efficacy
drug such as fingolimod appears to prevent this rebound provided it is started within 4 weeks after the last natalizumab infusion."
"Most
MSers stopping natalizumab are doing it because they are at high-risk
of developing PML. The major safety concern we have is so called
carry-over PML; i.e. PML that presents in the first few months after
starting fingolimod. I am aware of two cases of carry-over PML on
fingolimod. Carry-over PML is a problem in that we rely on the immune
response to clear you of PML; it takes about 6-8 weeks for fingolimod to
wash-out of your system and during this time PML can cause devastating
damage. Our practice, to prevent carry-over PML and rebound disease
activity, is to do a MRI and lumbar puncture shortly after the last
natalizumab infusion. If the spinal fluid analysis shows no JC virus DNA
and the MRI shows no evidence of asymptomatic PML we start fingolimod
within 4 weeks of the last natalizumab infusion. So far this practice
seems to be working; touch wood we have had no cases of carry-over
PML."
"In
clinic last week someone asked me about switching from natalizumab to
alemtuzumab? Alemtuzumab is an induction agent and hence you can't
reverse its action. If you developed carry-over PML after switching from
natalizumab to alemtuzumab the chances are you will die from the PML as
your immune system will not be able to respond quickly enough to clear
the virus. Post alemtuzumab it takes over 3 months for your immune
system to recover. For this reason I am telling my patients that it will
be much safer for them to switch to a maintenance agent, for example
fingolimod, for several months or years, before switching to alemtuzumab
post-natalizumab. The latter advice is not evidence-based and is
unlikely to become evidence-based in the future; this advice is based in
scientific principles on how the different DMTs affect your immune
system."
"For
UK MSers who read this blog we have finally been given the green-light
by NHS England to switch MSers at high-risk of PML on natalizumab to fingolimod, who have never been treated with interferon-beta or GA in the past.
Epub: Fox et al. MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study.Neurology. 2014 Mar.
OBJECTIVE: RESTORE was a randomized, partially placebo-controlled exploratory study evaluating multiple sclerosis (MS) disease activity during a 24-week interruption of natalizumab.
CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for MSers with MS taking natalizumab who are relapse-free for 1 year, stopping natalizumab increases the risk of MS relapse or MRI disease activity as compared with continuing natalizumab.
OBJECTIVE: RESTORE was a randomized, partially placebo-controlled exploratory study evaluating multiple sclerosis (MS) disease activity during a 24-week interruption of natalizumab.
METHODS: Eligible
MSers were relapse-free through the prior year on natalizumab and had
no gadolinium-enhancing lesions on screening brain MRI. MSers were
randomized 1:1:2 to continue natalizumab, to switch to placebo, or to
receive alternative immunomodulatory therapy (other therapies: IM
interferon β-1a [IM IFN-β-1a], glatiramer acetate [GA], or
methylprednisolone [MP]). During the 24-week randomized treatment
period, MSers underwent clinical and MRI assessments every 4 weeks.
CONCLUSIONS: MRI and clinical disease activity recurred in some patients during natalizumab interruption, despite use of other therapies.
CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for MSers with MS taking natalizumab who are relapse-free for 1 year, stopping natalizumab increases the risk of MS relapse or MRI disease activity as compared with continuing natalizumab.
http://multiple-sclerosis-research.blogspot.com/2014/04/clinic-speak-what-happens-when-you-stop.html?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+blogspot%2FWvYVL+%28Multiple+Sclerosis+Research%29
STUDY: Tysabri (Natalizumab) to Gilenya (fingolimod) washout in patients at risk of PML
Upon
withdrawing natalizumab, resumption of disease activity was soon
observed, beginning 3–4 months after the last dose of natalizumab
VIDEO: Dr. Timothy Vollmer
 |
| Dr. Timothy Vollmer |
There appears to be several different factors. One is genetics; the disease is more prevalent in people from Northern Europe. The second one is low Vitamin D levels early in life, and possibly in in-utero, increase the risk of MS subsequently," University of Colorado Doctor Tim Vollmer said.
He says people in Colorado are normally diagnosed with low-levels of Vitamin D. Some experts believe Vitamin D levels may be low in the state because of Coloradan's use of sunscreen.
Vollmer says new MS research and treatments are progressing at a remarkable rate.
"The field Multiple Sclerosis is one of the most rapidly evolving fields of medicine right now. We have eight FDA therapies and three that are likely to be approved within the next year to 18 months. In the last year or so, we've developed a new blood test that would identify patients who are at risk of some of the serious side effects of the drugs. As a consequence, we can now identify people who are likely to do very well on a certain drug with a very low risk," Vollmer said.
Wow! It's no wonder MS is seen as a Cash Cow: THESE MS DRUGS BROUGHT IN THE MOST MONEY LAST YEAR
Teva
soaring out in front on a single product and it is no surprise that the
Generics pack are waiting in the rear ready for the copaxone patents to
expire starting May 2014. However Biogen are backing the most winners
with a staggering $5.8 billion worth of business.
#1 Glaterimer acetate Teva $4.3 billion
#2 Avonex Biogen Idec $3.0 billion
#3 Gilenya Novartis $1.9 billion
#4 Tysabri Biogen Idec $1.7 billion
#5 Betaseron Bayer $1.1 billion
#6 Tecfidera Biogen Idec $0.9 billion
#7 Rebif EMD serono $0.6 billion
#8 Ampyra Biogen Idec $0.3 billion
#9 Aubagio Sanofi $0.2 billion
#10 Extavia Novartis $0.2 billion
#1 Glaterimer acetate Teva $4.3 billion
#2 Avonex Biogen Idec $3.0 billion
#3 Gilenya Novartis $1.9 billion
#4 Tysabri Biogen Idec $1.7 billion
#5 Betaseron Bayer $1.1 billion
#6 Tecfidera Biogen Idec $0.9 billion
#7 Rebif EMD serono $0.6 billion
#8 Ampyra Biogen Idec $0.3 billion
#9 Aubagio Sanofi $0.2 billion
#10 Extavia Novartis $0.2 billion
GOOD NEWS FOR MSers GOING OFF OF TYSABRI:
Gilenya (Fingolimod) reduces recurrence of disease activity after Tysabri (natalizumab) withdrawal
"Good lord! I'm beating MS": How the Earl of Durham is fighting illness with a veggie diet, meditation and doses of sunshine vitamin
The inexplicable and increasingly worrying symptoms had been
plaguing me for more than a year when, in December 2007, aged 46, I was
diagnosed with multiple sclerosis (MS).
There had been problems with
my balance to the point where I couldn’t walk without a stick, numbness
throughout my body, slurred speech and, most upsetting of all, a clumsiness in
my hands that left me unable to play the
guitar.
"Which MS Drug for Which Patient? The Debate Intensifies"
NOMINEE FOR MS NEWS CHANNEL BEST ARTICLE OF 2013 AWARD
The European approval of alemtuzumab (Lemtrada, Genzyme/Sanofi) means that there will soon be another new and exciting tool in the multiple sclerosis (MS) armamentarium. But how will this seemingly very effective agent fit in to current treatment?
 |
| Lily K. Jung Henson, MD |
The European approval of alemtuzumab (Lemtrada, Genzyme/Sanofi) means that there will soon be another new and exciting tool in the multiple sclerosis (MS) armamentarium. But how will this seemingly very effective agent fit in to current treatment?
NEUROLOGISTS NEED TO HAVE "HEIGHTENED VIGILANCE"
The knowledge that epilepsy and multiple sclerosis occur together more frequently than by chance should heighten vigilance for both when diagnosing or treating patients with either condition. For example, unexplained cognitive symptoms in a patient with multiple sclerosis may turn out to be partial complex seizures, whereas an episode of painful blurry vision in someone with epilepsy could indicate optic neuritis as the first symptom of multiple sclerosis. If seizures require treatment, an antiepileptic drug should be chosen that does not exacerbate preexisting symptoms of multiple sclerosis, such as ataxia, tremor or impaired cognition.
More research needs to be done to investigate the underlying reasons for the increased incidence of epilepsy in patients with multiple sclerosis, as well as an increased incidence of multiple sclerosis in patients with epilepsy. Inflammatory cortical demyelination in multiple sclerosis could cause neuronal loss and seizures. Could an inflammatory pathogenesis of epilepsy also lead to multiple sclerosis? As research continues to progress very rapidly in both of these disease states, maybe we won't have to wait long to find out.
The PML RESTORE trial: What did we learn about Tysabri, PML and multiple sclerosis?
The information from the RESTORE trial helped to clarify an important
question about whether or not Tysabri (natalizumab) can be used
intermittently. The results suggest that a planned interruption of
treatment results in a worsening of the MS. Clinical worsening occurred
in as little as 1 month, whereas MRI changes did not occur until after
the third month without natalizumab.
Click here to read more
Click here to read more
BREAKING NEWS ON PML: FDA probes brain infection in patient with MS drug PML
US
FDA raised an alert in Europe after emergence of a case of progressive
multifocal leukoencephalopathy (PML), following the administration of
Novartis multiple sclerosis drug Gilenya
FDA investigates multifocal leukoencephalopathy (PML) in patient on Novartis multiple sclerosis drug Gilenya
HERE'S A NEW EDITORIAL ABOUT TYSABRI AND THE PML PROBLEM FOR MSers NEEDING TO QUIT TYSABRI
Tysabri/Natalizumab discontinuation in the increasing complexity of multiple sclerosis therapy
Incontinence-related quality of life improved significantly during Tysabri
"Blocking
inflammation in the CNS does not just stop relapses, it can improve
fatigue in some people and as shown here can help with bladder function
also..."
HERE'S THE STUDY:
"Blocking
inflammation in the CNS does not just stop relapses, it can improve
fatigue in some people and as shown here can help with bladder function
also..."- UDI-6 and IIQ-7 scores were significantly improved in patients with MS following natalizumab treatment.
- The majority of patients showed improvement or stability in number of incontinence episodes per week and in number of micturitions per day after starting natalizumab.
- Natalizumab may reduce the impact of incontinence on QOL.
HERE'S THE STUDY:
A message from the Editor of MSnewsChannel.com
Here's a few of the FeatureStories we're working on for you: we will be posting 1 or 2 tomorrow & every day (usually) 7 days a week:
Editor
Stan Swartz
- HISTORY OF STEM CELLS: 15 PHOTO SLIDESHOW
- THE BEGINNING OF RICHARD COHEN'S STEM CELL JOURNEY
- What is a TENS machine? It might help MS
- MSer will swim 10-11 hours across lake
- Stressful life-events in childhood and risk of MS: Parental divorce is somehow associated with modestly increased risk of MS
- Legalize Medical Marijuana, Doctors Say in Survey! Neurologists reported the highest number of patients asking if medical marijuana might help the.
- NEW STUDY: MEDS HELP IMPROVE MSers STANDING BALANCE
- From Plant to Prescription: 5 Ways Marijuana Made It to the Market
- Pregabalin an Effective Alternative for Restless Legs Syndrome
- TYSABRI AS "1ST-LINE" TREATMENT FOR MS
- MARY TELLS ABOUT: “It was amazing...I was so thrilled that it gave my body the feelings it had pre-MS.”
- MS IS A DISCRIMINATORY DISEASE
- HOW THIS SUICIDE RELATES TO MSers: "The topic of suicide was thrust into the headlines recently with the death of L'Wren Scott, a fashion designer whose March 17 death was ruled a suicide by police"
- THE BEST WAY TO QUIT SMOKING THAT YOU HAVE NEVER READ ABOUT
- Can the bacteria in the GI Tract affect MS?
- CHILD NAMED ROTEM WAS INSPIRATION FOR AN INVENTION THAT ALLOWS MOBILITY-CHALLENGED LITTLE ONES TO EXPERIENCE WALKING
- PLUS MANY MORE!!
Editor
Stan Swartz
PS...Have a Story or Study you want posted? Or are you a Neurologist or Nurse and want to share some advice? e-mail at: stanswartz@mac.com
- We posted 5,560 Stories for Doctors, Nurses & Savvy MSers in 2013
- We're building the 12 MS Drug Treatment Channels at the top of this page & hope to finish them by June 1, 2014!
- Our 32 Columnists have written 210 articles for you since we started the Columns 3 months ago
- News is posted at Midnight 7 days a week
- 180,618 VISITORS!
Jayce Parente, Columnist, MSnewsChannel.com
 |
Jayce Parente, Columnist, MSnewsChannel.com |
Am I ok?
Are these MS symptoms?
Are they the potentially lethal PML symptoms?
I've been told to be "mindful" of PML symptoms yet PML symptoms and MS relapse symptoms are identical.
I know you're gonna say call my "Care Team" but what good is that when they are going to give me a script for a blood test in which it will take me a few days until I can have blood drawn only to wait a few days to get the results when I'm "supposed" to act QUICKLY?
So let me get this straight? I've taken a drug for 2 years that has been linked to causing progressive multifocal leukoencephalopathy (PML). I just stopped taking this drug and am currently detoxing from it.
I also have started to generate more intense symptoms SINCE stopping this drug. Are these MS symptoms?
Are they the potentially lethal PML symptoms?
I've been told to be "mindful" of PML symptoms yet PML symptoms and MS relapse symptoms are identical.
Well, identical with the exception of death or increased likelihood of seizures.
I've also been told if I suspect PML it is VERY important to respond quickly so a plasma exchange can be performed.
So, basically, am I supposed to wait for a seizure and I'm on the floor swallowing my tongue to figure out whether I'm having an MS or PML seizure?
So how do I tell?
Any of you guys have any ideas?
Since stopping the Tysabri I've been steadily degrading and gotten MUCH worse to a point I've been embarrassing myself
Update
MSers STOPPING TYSABRI DO IT BECAUSE THEY ARE AT HIGH-RISK OF DEVELOPING PML....
BUT STOPPING TYSABRI LEADS TO REBOUND IN MS DISEASE ACTIVITY
GILENYA APPEARS TO PREVENT THIS REBOUND IF IT'S STARTED WITHIN 4 WEEKS AFTER THE LAST TYSABRI INFUSION
"The study below confirms what we already know; stopping Tysabri/natalizumab leads to rebound in MS disease activity.
Switching to a DMT on a lower-tier of efficacy, i.e. interferon-beta or glatiramer acetate, or taking steroids does not prevent this rebound.
In comparison, a higher-efficacy drug such as
Gilenya/fingolimod appears to prevent this rebound provided it is
started within 4 weeks after the last Tysabri/natalizumab infusion."
"Most MSers stopping Tysabri/natalizumab are doing it because they are at high-risk of developing PML. The major safety concern we have is so called carry-over PML; i.e. PML that presents in the first few months after starting fingolimod.
I am aware of two cases of carry-over PML on fingolimod. Carry-over PML is a problem in that we rely on the immune response to clear you of PML; it takes about 6-8 weeks for fingolimod to wash-out of your system and during this time PML can cause devastating damage. Our practice, to prevent carry-over PML and rebound disease activity, is to do a MRI and lumbar puncture shortly after the last natalizumab infusion. If the spinal fluid analysis shows no JC virus DNA and the MRI shows no evidence of asymptomatic PML we start fingolimod within 4 weeks of the last natalizumab infusion. So far this practice seems to be working; touch wood we have had no cases of carry-over PML."
SHARE THIS BY CLICKING TINY ENVELOPE BELOW
BUT STOPPING TYSABRI LEADS TO REBOUND IN MS DISEASE ACTIVITY
GILENYA APPEARS TO PREVENT THIS REBOUND IF IT'S STARTED WITHIN 4 WEEKS AFTER THE LAST TYSABRI INFUSION
"The study below confirms what we already know; stopping Tysabri/natalizumab leads to rebound in MS disease activity.
Switching to a DMT on a lower-tier of efficacy, i.e. interferon-beta or glatiramer acetate, or taking steroids does not prevent this rebound.
 |
| Dr Gavin Giovannoni |
"Most MSers stopping Tysabri/natalizumab are doing it because they are at high-risk of developing PML. The major safety concern we have is so called carry-over PML; i.e. PML that presents in the first few months after starting fingolimod.
I am aware of two cases of carry-over PML on fingolimod. Carry-over PML is a problem in that we rely on the immune response to clear you of PML; it takes about 6-8 weeks for fingolimod to wash-out of your system and during this time PML can cause devastating damage. Our practice, to prevent carry-over PML and rebound disease activity, is to do a MRI and lumbar puncture shortly after the last natalizumab infusion. If the spinal fluid analysis shows no JC virus DNA and the MRI shows no evidence of asymptomatic PML we start fingolimod within 4 weeks of the last natalizumab infusion. So far this practice seems to be working; touch wood we have had no cases of carry-over PML."
SHARE THIS BY CLICKING TINY ENVELOPE BELOW
update
 |
| Dr. Gavin Giovannoni |
IMPORTANT STUDY FOR ALL MSers ON OR GOING OFF TYSABRI TO READ
A 24-week Tysabri treatment interruption study:
MRI and clinical disease activity recurred in some patients who stopped taking Tysabri, despite use of other therapies.
STUDY: First-line Tysabri/Natalizumab in Multiple Sclerosis
We are working on a Report of this. Until it is finished and we post it: Click here to read this Study
Thursday, May 15
FOR HEALTHCARE PROFESSIONALS ONLY: Tysabri/Natalizumab PML Risk Update: February 2014
37 PHOTO SLIDESHOW
Natalizumab PML Risk Update: February 2014
February 2014 natalizumab PML update. #MSBlog #MSResearch
"The following are the latest risk figures for PML as a result of being treated with natalizumab. Please note that the embedded slideshow is for health professionals only; I have been told by Biogen-Idec that if you are not a health professional you should not be reading it. if you are a MSer you should be reading my previous post designed for you."
"As of 4th February 2014 there have been 439 cases of natalizumab-associated PML; an increase of 9 cases from last month. The mortality associated with PML in this setting is currently 23%, i.e. 101 MSers have died as result of PML, The majority of the PML survivors have a poor functional outcome. You need to keep these figures in context of over 123,000 MSers have been treated with natalizumab."
"It is becoming increasingly clear that the numbers of MSers developing PML are falling due to the successful risk mitigation strategy that has been implemented Biogen-Idec with JC virus serological testing."
"The following is the most important slide for MSers regarding risks based on the three identified PML risk factors:
JCV serostatus
Duration of treatment
Previous exposure to immunosuppression
more
Natalizumab PML Risk Update: February 2014
February 2014 natalizumab PML update. #MSBlog #MSResearch
"The following are the latest risk figures for PML as a result of being treated with natalizumab. Please note that the embedded slideshow is for health professionals only; I have been told by Biogen-Idec that if you are not a health professional you should not be reading it. if you are a MSer you should be reading my previous post designed for you."
"As of 4th February 2014 there have been 439 cases of natalizumab-associated PML; an increase of 9 cases from last month. The mortality associated with PML in this setting is currently 23%, i.e. 101 MSers have died as result of PML, The majority of the PML survivors have a poor functional outcome. You need to keep these figures in context of over 123,000 MSers have been treated with natalizumab."
"It is becoming increasingly clear that the numbers of MSers developing PML are falling due to the successful risk mitigation strategy that has been implemented Biogen-Idec with JC virus serological testing."
"The following is the most important slide for MSers regarding risks based on the three identified PML risk factors:
JCV serostatus
Duration of treatment
Previous exposure to immunosuppression
more
Subscribe to:
Posts (Atom)